Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ZO regimen as first-line therapy for elderly follicular lymphoma
ChiCTR2400089176Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib and obinutuzumab in follicular lymphoma (FL), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Complete remission (CR) rate and MRD negative rate at 24 weeks. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
zanubrutinibobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2400089176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089176.